Evidence map›Paper›PMID 38597637›Full record

ArticleMicrobiology spectrum2024

Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases.

Aparna Bhanushali, Sachin Atre, Preethi Nair, Geethanjali Anilkumar Thandaseery, Sanchi Shah, Sanjana Kuruwa, Amrutraj Zade, Chaitali Nikam, Mangala Gomare, Anirvan Chatterjee

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. ThePeerJ · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Aparna BhanushaliHaystackAnalytics Pvt. Ltd., IIT Bombay, Mumbai, India.ORCID 0000-0001-8410-6520
Sachin AtreDr. D.Y. Patil Medical College Hospital and Research Centre, Pune, India.ORCID 0000-0003-2148-465X
Preethi NairHaystackAnalytics Pvt. Ltd., IIT Bombay, Mumbai, India.
Geethanjali Anilkumar ThandaseeryHaystackAnalytics Pvt. Ltd., IIT Bombay, Mumbai, India.
Sanchi ShahHaystackAnalytics Pvt. Ltd., IIT Bombay, Mumbai, India.
Sanjana KuruwaHaystackAnalytics Pvt. Ltd., IIT Bombay, Mumbai, India.
Amrutraj ZadeHaystackAnalytics Pvt. Ltd., IIT Bombay, Mumbai, India.
Chaitali NikamThyrocare Technologies Ltd., Navi Mumbai, India.
Mangala GomareBrihanMumbai Municipal Corporation, Mumbai, India.
Anirvan ChatterjeeHaystackAnalytics Pvt. Ltd., IIT Bombay, Mumbai, India.ORCID 0000-0002-7113-9718
Indian Institute of Technology Bombay · INBrihanmumbai Municipal Corporation · INDr. D. Y. Patil Medical College, Hospital and Research Centre · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment decisions for tuberculosis (TB) in the absence of full drug-susceptibility data can result in amplifying resistance and may compromise treatment outcomes. Genomics of IMPORTANCE: The current study is based on real-world data on the TB drug-resistance profile by whole-genome sequencing of 600 clinical samples from patients with TB in India. This study indicates the clinicians' reasons for sending samples for WGS, which is for difficult-to-treat cases and/or relapse and treatment failure. The study reports a significant proportion of cases with pre-XDR-TB strains that warrant policy makers' attention. It reflects the current iterative nature of the diagnostic tests under programmatic conditions that leads to delays in appropriate diagnosis and empirical treatment. India had an estimated burden of 2.95 million TB cases in 2020 and 135,000 multidrug-resistant cases. However, WGS profiles of

Indexed as

Antitubercular AgentsDNA-Directed RNA PolymerasesDrug Resistance, Multiple, BacterialExtensively Drug-Resistant TuberculosisMicrobial Sensitivity TestsMutationMycobacterium tuberculosisOxidoreductasesTuberculosis, Multidrug-ResistantWhole Genome SequencingAdolescentAdultAgedBacterial ProteinsFemaleHumansAntitubercular AgentsBacterial ProteinsDNA-Directed RNA PolymerasesInhA protein, MycobacteriumOxidoreductasesRifampinrpoB protein, Mycobacterium tuberculosisdrug-resistance mechanismsdrug-sensitivity testingIndiamolecular biologymolecular diagnosticsmultidrug resistantMycobacterium tuberculosisphylogenywhole-genome sequencing

Identifiers

PMID38597637
PMCPMC11064594
OpenAlexW4394692514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.